Military Health System Research Symposium (MHSRS)

Randomized Phase 2 of agenT-797 as a Pathogen-Agnostic Treatment of Hypoxemic Pneumonia/ARDS in Austere and Conflict Environments, T. Hammond, et al.

Presentation •August 6, 2026

Clinical Immunology Communications

Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy, T. Hammond, et al.

Article •May 20, 2026

American Thoracic Society (ATS)

Novel Invariant Natural Killer T Cell (agenT-797) and Interleukin-15 Superagonist (N-803) Combination Immunotherapy for Unresolving Coccidioides immitis Infection with Concurrent ARDS, T. Hammond, et al.

Poster •May 20, 2026

American Society of Gene & Cell Therapy (ASGCT)

agenT-797 Allogeneic iNKT Cell Therapy Reprograms Adaptive Immunity in Cancer and ARDS, M. Purbhoo, et al.

Poster •May 14, 2026

American Association for Cancer Research (AACR)

Phase II Study of agenT-797 (invariant Natural Killer T cells), Botensilimab (Fc-enhanced CTLA-4 Inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer , S. Cytryn, et al.

Poster •April 20, 2026

Keystone Symposia on Molecular and Cellular Biology

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis, T. Hammond, et al.

Poster •February 3, 2026

Society for Immunotherapy of Cancer (SITC)

AgenT-797, an Allogeneic iNKT Cell Therapy, Demonstrates Durable Clinical Activity in Solid Tumors: Updated Phase 1 Findings (LBA #1344), B. Garmezy, et al.

Poster •November 7, 2025

Oncogene

Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor, B. Garmezy, et al.

Article •July 11, 2025

Frontiers in Immunology

CAR-iNKT cells: redefining the frontiers of cellular immunotherapy, M. Niedzielska, et al.

Article •July 10, 2025

American Association for Cancer Research (AACR) IO

Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC), S. Cytryn, et al.

Poster •February 24, 2025

Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer, S. Cytryn, et al.

Presentation •February 24, 2025

American Society of Clinical Oncology GI (ASCO GI) 2025

TPS 515: A phase II study of agenT-797 (invariant natural killer T cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma, S. Cytryn, et al.

Poster •January 23-25, 2025

Society for Immunotherapy of Cancer (SITC) 2024

AgenT-797 iNKT Cell Therapy can be Combined with Immune Checkpoint Inhibitors and Bi-Specific Engagers to Improve the Anti-Tumor Response, M. Popis, et al.

Poster •November 6-10, 2024

PRAME-TCR iNKT Cell Therapy: Opportunity for Best-in-Class Off-the-Shelf Solid Tumor Therapy Targeting PRAME, P. Ibbett, et al.

Poster •November 6-10, 2024

The American Thoracic Society (ATS) 2024

Persistent SARS-CoV-2, COVID-19 Associated Acute Respiratory Distress Syndrome, Severe Coagulopathy and Massive Hemoptysis in a Renal Transplant Patient on Veno-Venous Extracorporeal Membrane Oxygenation, T. Hammond, et al.

Poster •May 21, 2024

American Association for Cancer Research (AACR) 2024

MiNK-215, an IL-15 armored FAP-targeting CAR iNKT Cell Therapy, effectively treats human organoid models of treatment-refractory MSS colorectal cancer (CRC) liver metastasis, S. Krishnan, et al.

Poster •April 8, 2024

Nature Communications

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome, T. Hammond, et al.

Article •February 6, 2024

Oncogene

Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT), B. Carneiro, et al.

Article •January 29, 2024

Society for Immunotherapy of Cancer (SITC) 2023

Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer, M. Purbhoo, et al.

Poster •November 3

International Cancer Immunotherapy Conference (CICON) 2023

Counteracting immune suppression and enhancing cytotoxic T cell activity with allogeneic invariant Natural Killer T (iNKT) cells expressing an armored CAR targeting fibroblast activation protein in an advanced solid tumor model system, M. van. Dijk, et al.

Poster •September 22-23

American Thoracic Society (ATS) International Conference 2023

Administration of Novel Allogeneic iNKT Cell Infusion (agenT-797) in Patients With Severe COVID-19 Acute Respiratory Distress Syndrome (CARDS) Receiving Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support, T. Hammond, et al.

Poster •May 19-24

American Society of Gene and Cell Therapy (ASGCT) 2023

Development of an allogeneic FAP-CAR iNKT cell therapy to modulate the immunosuppressive stroma and improve anti-tumor immunity Against non-small cell lung carcinoma, S. Boi, et al.

Poster •May 16-20

American Association for Cancer Research

Phase 1 study of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors, B. Carneiro, et al.

Poster •April 14 - 19

Society for Immunotherapy of Cancer (SITC) 2022

Phase 1 studies of agenT-797, a novel allogeneic invariant natural killer T cell therapy, for the treatment of patients with solid tumors or multiple myeloma, D. Stevens, et al.